Quick Dispatch:
Your surmount-1 tirzepatide non-diabetic obesity trial SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surmount-1 tirzepatide non-diabetic obesity trial SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants ships.
Need Help?
Questions about surmount-1 tirzepatide non-diabetic obesity trial SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surmount-1 tirzepatide non-diabetic obesity trial SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants in your area.
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
20.76
Tirzepatide vs semaglutide: A new battle in obesity treatment
23.56
How Did Diabetes Medications Become Weight Loss Meds? Beyond Journal Club on SURMOUNT-1 Trial – Core IM Podcast
23.41
SURMOUNT-1: Tirzepatide Drastically Reduces Weight in Obese Patients
29.12
Tirzepatide and the 10‐year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three‐year SURMOUNT‐1 trial - Hankosky
20.85
SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes
27.77
Tirzepatide lowers body weight for adults with obesity, regardless of disease duration
26.31
